Introduction
Hodgkin's lymphoma (HL) is a highly curable malignant disease. Contemporary treatment for children and adolescents with Hodgkin's disease often uses a combined-modality approach with multi-agent chemotherapy and involved-field radiotherapy. This approach has yielded excellent results, with long-term disease-free survival ranged from 85% to 100% in patients with early-stage disease and of more than 60% in those with more advanced disease [1] . Because cure is likely for the majority of children presenting with HL, attention to long-term treatment complications has become increasingly important. Risk-adapted therapy for children with HL is directed toward high survival, minimal toxicity and optimal quality of life. This approach assigns intensity of therapy according to the risk criteria at presentation, with the parameters most frequently used to assign risk are the presence of "B" symptoms, bulk of presenting mass, mediastinal lymphadenopathy, extra nodal extension, number of involved nodal regions and Ann Arbor stage [2] . The objectives of this study are to assess the outcome of the HL patients treated with risk-adapted therapy approach at pediatric oncology department in South Egypt Cancer Institute (SECI) and to assess the prognostic factors of survival in pediatric HL patients.
(ESR), lactic dehydrogenase (LDH), thyroid function test (TFT), sex hormones and bone marrow biopsy was done for patients with systemic (B) symptoms or stages (II-IV)}, chest X-ray and cervical, thoracic, abdominal and pelvic computed tomography (CT) scan with contrast. Pulmonary function test and echocardiography were done as baseline for follow up. Excisional biopsy was obtained from presenting lymphadenopathy and specimens were subjected to morphological studies and immunohistochemical tests by using CD15, CD30 and CD20, histopathological classification was done according to Revised 5 Gy with modification based on patient's age, the presence of bulky disease, normal tissue concerns and potential acute and long-term effects. Radiation therapy was given using antero-posterior/postero-anterior fields, and started within 4 weeks of last chemotherapy cycle. Gross target volume was enlarged lymph node, clinical target volume was the anatomical compartment of enlarged lymph node and planning target volume was 1 cm margin to clinical target volume. An anterior laryngeal block was used if it did not shield involved nodes in case of radiation therapy to cervical region. If the axillae were to be treated, humeral head blocks were used. After-therapy monitoring: After completion of chemotherapy, patients was followed monthly in the first year, every 3 months in the 2 nd and 3 rd years.. Follow-up examinations was done by physical examination, chest X-ray, routine laboratory investigations (CBC and ESR) and CT scans according to initial presentation. Specific evaluation of late effects including hormonal assessment (TFT and sex hormones), pulmonary function test, echocardiography and examination of bone and soft tissues was done.
Evaluation of remission:
Statistical analysis: Overall survival (OS) was calculated from the first day of chemotherapy to the date of the last follow up or death due to any cause. Event free survival (EFS) was calculated from the first day of chemotherapy to an event (death due to any cause, progression after PR, relapse or a second malignancy) or to the date of the last follow up contact for patients who did not experience any event. OS and EFS were estimated with Kaplan-Meier method and differences were assessed by the log-rank test. Coxregression was used in multivariate analysis.
Results
From January 2009 to January 2014. 34 patients with previously untreated HL were enrolled into this study.
Patients' characteristics: are shown in table (2). The median age was 8 years (range 4-16 years). Twenty patients (60%) were males and 14 patients (40%) were females with male to female ratio 1.4:1. Four patients (11.8%) were stage I, 16 patients (47.1%) were stage II, 12 patients (35.3%) were stage III and 2 patients (5.8%) were stage IV. Risk stratification revealed 6 patients (17.6%) in LR group, 18 patients (52.9%) in IMR group and 10 patients (29.4%) in HR group. Twenty one patients (61.8%) had systemic "B" symptoms. Bulky disease was reported in 9 patients (26.5%) with 6 patients (17.6%) had bulky mediastinal mass and 3 patients (8.8%) had bulky peripheral nodal mass.
Cervical lymph node enlargement was the most predominant site 85.3% followed by axillary in 50%, abdomen in 47% and mediastinum in 28.6%. Extra nodal involvement was recorded in 9 patients (26.5%), splenomegaly in 17.6%, hepatomegaly in 14.7%. Nineteen patients (58.8%) had ≥ 4 nodal regions. Twenty six patients (76.5%) had mixed cellularity, 14 patients had nodular sclerosis and 3 patients had lymphocytic predominant. Four patients (11.8%) had leukocytosis, 19 patients (55.9%) had anemia, ESR was elevated in 14 patients (41.2%).
Response to treatment: After 2 cycles of chemotherapy, 12 patients (35.3%) achieved CR (five patients (83.3%) in LR, 6 patients (33.3%) in IMR and one patient (10%) in HR), 22 patients (64.7%) had PR. At the end of chemotherapy, Thirty-three out of 34 patients (97.1%) evaluated, 30/33 patients (90.9%) had CR ( 6 patients (100%) in LR, 17 patients (94.4%) in IMR and 7 patients (70%) in HR) and 3/33 patients (9.1%) had PD (one patient in IMR and 2 patients in HR).
Treatment failure: There were 5 treatment failures, 3/33 patients (9.1%) had progressive disease (one patient of IMR group and two of HR group) and 2/30 patients (6.7%) had relapse (two of HR group). One patient relapsed outside the irradiated field, the other relapsed within and outside the irradiated field. They occurred at 7, 22 months after completion of radiotherapy. Both were salvaged by second line chemotherapy ICE (ifosfamide, carboplatin and etoposide) table (1) followed by radiotherapy with complete remission in one patient and partial remission in the other patient who died from hepatocellular failure.
Toxicity: Morbidity was mostly observed in HR group. As regard to the early complications, bone marrow suppression was the most frequent complication (8.8%) followed by chest infection. Acute gonadal failure occurred in one patient (post pubertal) after receiving pelvic radiotherapy in spite of oophrepexy and she is now on hormonal therapy. Late effects of treatment were detected in patients on follow up in the form of hypothyroidism in 2 patients (8.8%) and restrictive pulmonary function in one patient (2.9%) while no cardiac complications occurred. Survival analysis: The 3-years OS and EFS rates (± SE) were 91.2% ± 5.3% and 82.3% ± 7.3% respectively (Fig 1, 2) . Factors affecting OS and EFS are shown in 
year OS were 100%, 94.4% ± 5.4% versus 80% ± 13.4% respectively (p=0.07) and 3-year EFS were 100%, 94.4% ± 5.4% versus 50% ± 17.4% respectively (p=0.005) (Fig 3, 4) Multivariate analysis revealed that the significant independent factors for inferior EFS were "B" symptoms (p=0.047, HR: 2.1, 95% CI: 0.6-3.8) and anemia (p=0.025, HR: 3.8, 95% CI:1.2-9.6). However, the significant independent factors for lower OS were hypoalbuminemia (p=0.013, HR: 5.4, 95% CI: 0.8-9.1) and anemia (p= 0.048, HR: 2.6, 95% CI: 0.9-5.4). 
Discussion
Hodgkin lymphoma is a neoplasm in which survival and cure has improved dramatically over the 50 years with survival rate reaching 94%. Because cure is likely for the majority of children and adolescents presenting with HL, attention to long-term treatment complications has become increasingly important. Risk-adapted combined modality treatment protocols, which assign intensity of therapy according to risk features at diagnosis have become a standard treatment approach for pediatric malignancies that are highly curable with contemporary therapy while reducing therapy-related complications [8].
In the current study, the median age was 8 years which is less than that reported by El Badawy et al In our study, the clinical presentation of nodal disease is comparable to what was reported in the literature as cervical lymphadenopathy was the most predominant site reported in (85.3%) followed by axillary, abdominal and mediastinal involvement which is also in agreement with other studies reported by El Badawy et al 61.8% of patients had systemic "B" symptoms which is comparable to Schwatez et al [7] and El Badawy et al [8] . Bulky disease was seen in 9 patients (26.7%) (mediastinum in 6 patients and peripheral lymph nodes in 3 patients) which is similar to Ali et al [12] . [15] reported that mixed cellularity subtype was more prevalent in children less than 10 years old, but less likely in older children/adolescents which is in agreement with our study with the majority of patient's age was found below 10 years. The explanation of high prevalence of mixed cellularity subtype may be explained by increased risk factors in developing countries rather than developed countries which also can explain the high frequency of advanced stages and "B" symptoms which is associated with mixed cellularity subtype other than nodular sclerosis subtype. Univariate analysis of prognostic factors of OS and EFS revealed that there was significant influence of advanced stage, extra nodal involvement, "B" symptoms, bulky disease, leukocytosis, lymphopenia, anemia, hypoalbuminemia and elevated ESR on inferior EFS while this was not translated into significant affection of the OS except for extra nodal involvement and lymphopenia.
In Egypt, Ali et al [12] reported that many factors greatly affect EFS and OS which were histology, "B" symptoms, disease bulk and response to therapy but Smith et al [16] reported that there were many factors affecting OS and DFS as stage, histology, "B" symptoms, bulky disease, number of nodal regions, leukocytosis, anemia and elevated ESR.
There are multiple prognostic factors identified in selected multi-institutional studies, In the Stanford/St. Jude/Dana Farber Cancer Institute consortium, male gender; stage IIB, IIIB, or IV disease; white blood cell count of 11,500/mm 3 or higher; and hemoglobin lower than 11.0 g/dL were significant prognostic factors for inferior disease-free survival and overall survival (OS) [16] , in the Society for Paediatric Oncology and Haematology (GPOH-95) study, "B" symptoms, histology, and male gender were adverse prognostic factors for EFS on multivariate analysis [23] . In the Children Cancer Group (CCG-5942) study, the combination of "B" symptoms and bulky disease was associated with an inferior outcome [19] , and in St. Jude study, Hudson et al found that only leukocytosis and anemia were both associated with worse outcome (p= .046 and p=.003 respectively) [2].
In our study, multivariate analysis revealed that B symptoms (p=0.047, HR: 2.1, 95% CI: 0.6-3.8) and hemoglobin <11gm (p=0.025, HR: 3.8, 95% CI: 1.2-9.6) are the significant independent factors for inferior EFS. In Egypt, Ali et al [12] found that lymphocytic depletion pathological subtype was the only significant predictor of lower EFS and El-Badway et al [8] reported that only statistically significant prognostic indicator for OS and DFS was the relation between the DFS and the initial response to chemotherapy.
Conclusion
Treatment results of HL in pediatric oncology department, SECI, Assiut University using risk-adapted combined-modality therapy with ABVD/COEP and IFRT has high efficacy with minimal toxicity. "B" symptoms and anaemia were the significant independent factors for lower EFS but hypoalbuminemia and anemia were significant factors for inferior OS.
